45 related articles for article (PubMed ID: 11586094)
1. Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters.
Merati K; said Siadaty M; Andea A; Sarkar F; Ben-Josef E; Mohammad R; Philip P; Shields AF; Vaitkevicius V; Grignon DJ; Adsay NV
Am J Clin Oncol; 2001 Oct; 24(5):447-52. PubMed ID: 11586094
[TBL] [Abstract][Full Text] [Related]
2. Relationship between neural alteration and perineural invasion in pancreatic cancer patients with hyperglycemia.
Li J; Ma Q; Liu H; Guo K; Li F; Li W; Han L; Wang F; Wu E
PLoS One; 2011 Feb; 6(2):e17385. PubMed ID: 21386984
[TBL] [Abstract][Full Text] [Related]
3. Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome.
Fujii S; Mitsunaga S; Yamazaki M; Hasebe T; Ishii G; Kojima M; Kinoshita T; Ueno T; Esumi H; Ochiai A
Cancer Sci; 2008 Sep; 99(9):1813-9. PubMed ID: 18616529
[TBL] [Abstract][Full Text] [Related]
4. EGFR, but not COX-2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival.
Fagman JB; Ljungman D; Falk P; Iresjö BM; Engström C; Naredi P; Lundholm K
Oncol Lett; 2019 Jun; 17(6):5361-5368. PubMed ID: 31186753
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of urinary prostaglandin E2 metabolite and pancreatic cancer risk.
Cui Y; Shu XO; Li HL; Yang G; Wen W; Gao YT; Cai Q; Rothman N; Yin HY; Lan Q; Xiang YB; Zheng W
Int J Cancer; 2017 Dec; 141(12):2423-2429. PubMed ID: 28815606
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic stellate cell: Pandora's box for pancreatic disease biology.
Bynigeri RR; Jakkampudi A; Jangala R; Subramanyam C; Sasikala M; Rao GV; Reddy DN; Talukdar R
World J Gastroenterol; 2017 Jan; 23(3):382-405. PubMed ID: 28210075
[TBL] [Abstract][Full Text] [Related]
7. Hormophysa triquerta polyphenol, an elixir that deters CXCR4- and COX2-dependent dissemination destiny of treatment-resistant pancreatic cancer cells.
Aravindan S; Ramraj S; Kandasamy K; Thirugnanasambandan SS; Somasundaram DB; Herman TS; Aravindan N
Oncotarget; 2017 Jan; 8(4):5717-5734. PubMed ID: 27974694
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of cancer dissemination along nerves.
Amit M; Na'ara S; Gil Z
Nat Rev Cancer; 2016 Jun; 16(6):399-408. PubMed ID: 27150016
[TBL] [Abstract][Full Text] [Related]
9. Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity.
Gonnermann D; Oberg HH; Kellner C; Peipp M; Sebens S; Kabelitz D; Wesch D
Oncoimmunology; 2015 Mar; 4(3):e988460. PubMed ID: 25949900
[TBL] [Abstract][Full Text] [Related]
10. Galanin modulates the neural niche to favour perineural invasion in head and neck cancer.
Scanlon CS; Banerjee R; Inglehart RC; Liu M; Russo N; Hariharan A; van Tubergen EA; Corson SL; Asangani IA; Mistretta CM; Chinnaiyan AM; D'Silva NJ
Nat Commun; 2015 Apr; 6():6885. PubMed ID: 25917569
[TBL] [Abstract][Full Text] [Related]
11. Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.
Knab LM; Grippo PJ; Bentrem DJ
World J Gastroenterol; 2014 Aug; 20(31):10729-39. PubMed ID: 25152576
[TBL] [Abstract][Full Text] [Related]
12. COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis.
Pomianowska E; Schjølberg AR; Clausen OP; Gladhaug IP
BMC Cancer; 2014 Jun; 14():458. PubMed ID: 24950702
[TBL] [Abstract][Full Text] [Related]
13. Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer.
Swierczynski J; Hebanowska A; Sledzinski T
World J Gastroenterol; 2014 Mar; 20(9):2279-303. PubMed ID: 24605027
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor.
Charo C; Holla V; Arumugam T; Hwang R; Yang P; Dubois RN; Menter DG; Logsdon CD; Ramachandran V
Pancreas; 2013 Apr; 42(3):467-74. PubMed ID: 23090667
[TBL] [Abstract][Full Text] [Related]
15. The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma.
Hillion J; Smail SS; Di Cello F; Belton A; Shah SN; Huso T; Schuldenfrei A; Nelson DM; Cope L; Campbell N; Karikari C; Aderinto A; Maitra A; Huso DL; Resar LM
Pancreatology; 2012; 12(4):372-9. PubMed ID: 22898640
[TBL] [Abstract][Full Text] [Related]
16. Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.
Kirane A; Toombs JE; Ostapoff K; Carbon JG; Zaknoen S; Braunfeld J; Schwarz RE; Burrows FJ; Brekken RA
Clin Cancer Res; 2012 Sep; 18(18):5031-42. PubMed ID: 22829202
[TBL] [Abstract][Full Text] [Related]
17. Chronic inflammation in cancer development.
Multhoff G; Molls M; Radons J
Front Immunol; 2011; 2():98. PubMed ID: 22566887
[TBL] [Abstract][Full Text] [Related]
18. Involvement of COX-2/PGE(2) Pathway in the Upregulation of MMP-9 Expression in Pancreatic Cancer.
Bu X; Zhao C; Dai X
Gastroenterol Res Pract; 2011; 2011():214269. PubMed ID: 21760774
[TBL] [Abstract][Full Text] [Related]
19. Heparanase-1 and Cyclooxygenase-2: prognostic indicators of malignancy in pheochromocytomas.
Zhu Y; He HC; Yuan F; Zhang J; Rui WB; Zhao JP; Shen ZJ; Ning G
Endocrine; 2010 Aug; 38(1):93-9. PubMed ID: 20960108
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer.
Hermanova M; Karasek P; Tomasek J; Lenz J; Jarkovsky J; Dite P
World J Gastroenterol; 2010 Apr; 16(15):1879-84. PubMed ID: 20397266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
